influenza
vaccin
target
highli
variabl
surfac
glycoprotein
hemagglutinin
neuraminidas
caus
inconveni
vaccin
everi
year
reason
develop
univers
vaccin
target
conserv
viral
compon
need
studi
gener
recombin
adenoviru
rad
vaccin
encod
nucleoprotein
np
influenza
viru
design
radnp
balbc
mice
immun
intranas
sublingu
radnp
vaccin
subsequ
challeng
lethal
dose
heterolog
well
homolog
influenza
virus
found
intranas
immun
radnp
elicit
strong
mucos
iga
respons
well
stronger
tcell
respons
toward
immunodomin
k
restrict
np
epitop
sublingu
immun
importantli
singl
intranas
sublingu
immun
radnp
provid
potent
protect
homolog
heterolog
influenza
viru
challeng
result
suggest
recombin
radnp
could
univers
vaccin
candid
mucos
administr
influenza
viru
influenza
viru
import
respiratori
pathogen
account
million
infect
respons
death
annual
worldwid
recent
newli
emerg
influenza
viru
subtyp
infect
human
caus
signific
public
health
concern
exampl
sinc
sever
human
case
highli
pathogen
avian
influenza
viru
infect
first
report
hong
kong
late
hundr
addit
confirm
case
human
infect
viru
report
lethal
outcom
document
case
also
new
swinehumanavianorigin
influenza
viru
emerg
mexico
result
worldwid
pandem
moreov
recent
outbreak
avian
influenza
viru
china
claim
multipl
human
live
number
report
human
case
grow
continu
henc
exampl
underscor
necess
better
prepared
potenti
influenza
viru
pandem
caus
differ
influenza
viru
strain
vaccin
costeffect
way
control
andor
prevent
influenza
outbreak
howev
liveattenu
inactiv
influenza
vaccin
current
licens
human
use
design
induc
strainspecif
humor
immun
offer
crossprotect
differ
strain
influenza
viru
express
sequenti
andor
conform
relat
uniqu
viral
surfac
protein
gener
random
antigen
chang
influenza
viru
frequent
undergo
thu
develop
vaccin
offer
broadrang
protect
multipl
strain
influenza
viru
immens
benefici
public
health
develop
influenza
vaccin
import
consid
immun
respons
elicit
vaccin
target
viral
antigen
highli
conserv
among
multipl
influenza
viru
strain
influenza
viru
nucleoprotein
np
contain
conserv
immunodomin
tcell
epitop
associ
induct
crossprotect
immun
heterolog
heterosubtyp
influenza
viru
infect
previous
shown
immun
recombin
adenoviru
rad
vaccin
encod
conserv
influenza
antigen
np
gener
crossreact
immun
respons
provid
protect
lethal
viru
challeng
mice
accordingli
present
studi
gener
recombin
adenoviru
express
fulllength
np
radnp
deriv
influenza
viru
apuerto
rico
evalu
potenti
mucos
vaccin
candid
could
offer
broadrang
crossprotect
multipl
strain
influenza
viru
focus
advantag
adopt
mucos
vaccin
strategi
shown
effect
target
system
mucos
immun
parenter
vaccin
strategi
addit
compar
vaccinationinduc
immun
respons
gener
follow
administr
candid
vaccin
viru
via
two
differ
intranas
sublingu
mucos
rout
femal
balbc
mice
weekold
obtain
orient
bio
seoul
korea
mice
maintain
specif
pathogenfre
condit
experiment
facil
ewha
woman
univers
viral
rna
viru
acquir
use
qiaamp
minelut
viru
spin
kit
qiagen
valencia
ca
accord
manufactur
instruct
cdna
correspond
np
gene
gener
rtpcr
use
forward
primer
contain
kpni
restrict
enzym
site
kozak
sequenc
enhanc
translat
revers
primer
contain
stop
codon
xbai
restrict
enzym
site
terminu
whole
open
read
frame
digest
kpn
ixba
doubl
digest
insert
pshuttlecmv
vector
gener
replicationdefect
adenoviru
serotyp
np
sequenc
first
insert
adenoviru
genom
homolog
recombin
describ
previous
subsequ
recombin
adenovir
dna
contain
np
gene
transfect
cell
gener
radnp
viru
mock
adenoviru
radmock
gener
method
use
vacant
pshuttlecmv
vector
recombin
adenovirus
amplifi
cell
purifi
doubl
cscl
densitygradi
ultracentrifug
express
np
protein
radnp
confirm
infect
cell
multipl
infect
moi
immunoblot
use
mous
polyclon
antiserum
horseradish
peroxidas
hrp
conjug
goat
antimous
igg
invitrogen
eugen
secondari
antibodi
extract
cellular
protein
cell
cell
lysat
prepar
resuspend
cell
pellet
buffer
contain
mm
trishcl
mm
sodium
chlorid
sodium
deoxychol
sd
clear
supernat
pellet
separ
centrifug
femal
balbc
mice
kept
specif
pathogenfre
condit
vaccin
weekold
mice
inocul
vari
dose
radnp
vaccin
intranas
sublingu
sl
rout
immun
mice
lightli
anesthet
isofluran
hana
pharm
kyonggido
korea
plaqu
form
unit
pfu
radnp
pfu
radmock
volum
phosphatebuff
salin
pb
appli
nostril
sl
immun
mice
anesthet
intraperiton
inject
mgkg
bodi
weight
ketamin
yuhan
co
seoul
korea
mgkg
bodi
weight
xylazin
hydrochlorid
bayer
kyonggido
korea
describ
elsewher
forcep
place
tongu
mous
mouth
stretch
open
total
volum
vaccin
kept
avoid
swallow
effect
sl
group
secondarili
immun
procedur
two
week
primari
immun
three
week
last
immun
mice
lightli
anesthet
isofluran
challeng
ld
aphilippin
avietnam
anim
studi
perform
accord
guidelin
ewha
woman
univers
institut
anim
care
use
committe
iacuc
approv
five
day
post
challeng
subset
mice
sacrif
tracheotomi
execut
lung
airway
wash
ml
pb
collect
bronchoalveolar
lavag
bal
fluid
centrifug
supernat
use
measur
secretori
iga
titer
blood
acquir
retroorbit
plexu
heparin
capillari
tube
centrifug
serum
collect
store
antibodi
titer
immun
mice
measur
direct
enzymelink
immunosorb
assay
elisa
briefli
coat
antigen
pfu
viru
allanto
fluid
disrupt
triton
next
plate
coat
split
influenza
viru
dilut
pb
incub
overnight
block
pb
contain
nonfat
milk
tween
h
rt
sampl
sera
bal
fluid
ad
serial
dilut
incub
h
wash
step
pb
contain
tween
hrpconjug
goat
antimous
igg
invitrogen
hrpconjug
goat
antimous
iga
zyme
laboratori
san
francisco
ca
secondari
antibodi
measur
npspecif
igg
sera
npspecif
iga
bal
fluid
respect
color
develop
kpl
gaithersburg
md
ad
stop
ad
h
po
color
develop
analyz
nm
thermo
ex
vantaa
finland
five
day
influenza
viru
challeng
subset
group
euthan
influenza
vial
titer
lung
measur
describ
elsewher
briefli
lung
tissu
remov
pb
process
cell
strainer
bd
labwar
franklin
lake
nj
ml
mem
supernat
collect
centrifug
viru
titer
supernat
analyz
standard
plaqu
assay
subconflu
mdck
cell
data
express
pfu
per
gram
lung
tissu
lung
perfus
ml
pb
includ
uml
heparin
sigma
st
loui
mo
use
syring
needl
right
ventricl
dissect
collect
obtain
singlecel
suspens
tissu
homogen
ml
iscov
modifi
dulbecco
medium
imdm
cell
strainer
follow
centrifug
lymphocyt
resuspend
fresh
imdm
erythrocyt
remov
red
blood
cell
lyse
buffer
sigma
wash
imdm
cell
wash
two
time
fac
buffer
fb
nan
pb
block
purifi
rat
antimous
bd
pharmingen
san
diego
ca
streptavidin
invitrogen
cell
stain
antimous
clone
biolegend
san
diego
ca
antimous
clone
biolegend
k
np
tyqrtralv
tetramerp
stain
cell
fix
wtvol
paraformaldehyd
analyz
use
facscalibur
flow
cytomet
bd
bioscienc
san
diego
ca
flowjo
softwar
treestar
inc
ashland
data
plot
error
differ
comparison
conduct
use
unpair
twotailor
student
ttest
differ
consid
statist
signific
p
valu
full
length
code
region
np
gene
control
cmv
promot
follow
kozak
sequenc
enhanc
translat
gene
insert
polyadenyl
stop
signal
polya
insert
earli
region
adenoviru
genom
homolog
recombin
result
gener
recombin
replicationdefect
adenoviru
express
np
radnp
figur
proper
express
np
recombin
adenoviru
evalu
infect
cell
radnp
conduct
immunoblot
analysi
infect
cell
lysat
use
polyclon
antibodi
detect
robust
singl
band
approxim
molecular
weight
kda
repres
np
radnpinfect
cell
lysat
howev
band
detect
uninfect
cell
lysat
radmockinfect
cell
lysat
use
neg
control
figur
order
determin
optim
rout
dose
radnp
vaccin
elicit
appropri
influenza
viru
npspecif
immun
respons
balbc
mice
inocul
intranas
sublingu
either
pfu
radnp
also
mice
immun
intranas
pfu
radmock
use
neg
control
preliminari
studi
singl
sl
immun
radnp
insuffici
produc
detect
immunogenspecif
antibodi
level
balbc
mice
data
shown
therefor
order
enhanc
efficaci
immunogenspecif
antibodi
respons
sl
vaccin
sublingu
prime
mice
boost
two
week
first
immun
use
vaccin
scheme
use
prime
howev
mice
immun
intranas
receiv
singl
immun
indic
dose
radnp
radmock
subsequ
three
week
respect
final
immun
sera
harvest
immun
mice
level
igg
immun
sera
determin
via
elisa
use
detergentdisrupt
viru
coat
antigen
sl
vaccin
group
receiv
radnp
elicit
signific
level
serum
igg
compar
control
mice
given
radmock
figur
interestingli
mice
immun
via
sl
rout
gener
compar
level
serum
igg
titer
regardless
administ
vaccin
dose
mice
immun
via
rout
show
signific
dosedepend
differ
serum
igg
titer
two
vaccin
dose
use
serum
igg
level
determin
sera
harvest
mice
day
postchalleng
observ
signific
increas
igg
titer
mice
vaccin
intranas
either
dose
radnp
howev
increas
serum
igg
titer
follow
observ
sublingu
vaccin
mice
summari
data
indic
sl
immun
radnp
elicit
consider
level
npspecif
serum
igg
follow
radnp
immun
significantli
increas
serum
igg
level
compar
prechalleng
level
intranas
immun
mice
sublingu
immun
mice
addit
level
npspecif
mucos
iga
bal
collect
day
evalu
observ
extens
level
iga
titer
detect
mice
vaccin
intranas
radnp
regardless
administ
vaccin
dose
also
observ
follow
pfu
radnp
immun
increas
mucos
iga
level
compar
prechalleng
level
intranas
immun
mice
expect
bal
fluid
collect
mice
immun
radmock
contain
detect
level
mucos
iga
interestingli
howev
detect
mucos
iga
bal
collect
mice
given
radnp
via
sl
rout
figur
taken
togeth
result
suggest
rad
vectorbas
vaccin
express
np
gene
viru
capabl
elicit
npspecif
immun
respons
singl
immun
radnp
via
rout
suffici
induc
strong
system
well
mucos
immun
viru
repres
increas
serum
igg
mucos
iga
level
respect
previou
studi
report
influenza
viru
np
contain
k
restrict
immunodomin
tcell
epitop
amino
acid
domin
tcell
respons
elicit
influenza
viru
infect
order
determin
abil
radnp
vaccin
induc
tcell
respons
mention
epitop
level
k
np
tetramerspecif
tcell
recruit
lung
follow
radnp
vaccin
subsequ
evalu
briefli
mice
immun
either
pfu
radnp
immun
sl
radnp
use
primeandboost
vaccin
regimen
aforement
group
mice
immun
radmock
use
neg
control
immun
mice
challeng
lethal
dose
day
postchalleng
mice
lung
harvest
k
np
tetramerspecif
tcell
frequenc
determin
via
flow
cytometri
expect
observ
signific
increas
percentag
total
lung
cell
k
np
tetramerspecif
cell
lung
mice
receiv
radnp
via
rout
compar
lung
control
mice
receiv
radmock
figur
moreov
increas
npspecif
tcell
recruit
dosedepend
higher
percentag
total
lung
cell
npspecif
cell
detect
mice
receiv
pfu
dose
compar
receiv
pfu
figur
howev
observ
signific
differ
level
k
np
tetramerspecif
cell
sl
immun
group
compar
radmock
immun
control
group
notwithstand
dose
radnp
vaccin
administ
figur
phenomena
underscor
similar
trend
observ
serum
igg
mucos
iga
level
anim
receiv
differenti
dose
radnp
vaccin
via
rout
order
determin
whether
radnp
immun
confer
protect
homolog
influenza
viru
infect
mice
challeng
ld
live
viru
three
week
last
respect
immun
regimen
data
show
group
receiv
immun
radnp
regardless
administ
vaccin
dose
surviv
lethal
challeng
demonstr
consider
resist
weight
loss
figur
b
howev
mice
receiv
either
dose
radnp
via
sl
rout
well
control
mice
receiv
radmock
unimmun
mice
succumb
infect
day
postchalleng
figur
b
interestingli
howev
lung
viru
titer
day
postchalleng
detect
similar
level
immun
group
figur
probabl
radnp
may
induc
longlast
innat
immun
contribut
complementarili
specif
immun
arm
control
diseas
uncharacter
mechan
result
protect
may
necessarili
correl
viru
titer
detect
lung
upon
lethal
challeng
overal
result
indic
immun
radnp
confer
complet
protect
lethal
homolog
viru
challeng
allow
compet
viru
replic
perpetu
even
day
postchalleng
order
determin
whether
immun
radnp
offer
crossprotect
heterolog
andor
heterosubtyp
influenza
infect
immun
mice
challeng
week
last
respect
immun
regimen
first
investig
protect
efficaci
radnp
immun
heterolog
influenza
viru
infect
subtyp
mice
challeng
lethal
dose
monitor
daili
bodi
weight
chang
mortal
group
mice
receiv
immun
pfu
radnp
experienc
weight
loss
anim
surviv
lethal
challeng
group
receiv
immun
pfu
radnp
experienc
somewhat
heavier
weight
loss
compar
group
receiv
higher
dose
anim
surviv
challeng
figur
howev
anim
receiv
sl
immun
experienc
substanti
weight
loss
interestingli
observ
anim
receiv
pfu
vaccin
viru
via
sl
rout
surviv
lethal
challeng
wherea
anim
receiv
pfu
vaccin
viru
via
rout
succumb
challeng
next
order
evalu
heterosubtyp
protect
offer
radnp
vaccin
mice
challeng
lethal
dose
influenza
aphilippin
avietnam
monitor
daili
bodi
weight
chang
mortal
mice
immun
radnp
via
sl
rout
notwithstand
administ
vaccin
dose
suffer
consider
weight
loss
succumb
death
within
day
follow
philippin
influenza
viru
challeng
figur
contrast
group
immun
anim
receiv
either
pfu
vaccin
complet
protect
experienc
minim
weight
loss
follow
aphilippin
challeng
figur
overal
influenza
avietnam
challeng
produc
steeper
weight
loss
anim
compar
influenza
viru
challeng
sl
immun
group
receiv
either
pfu
vaccin
suffer
quick
sever
weight
loss
upon
challeng
thereaft
succumb
death
within
day
figur
group
receiv
pfu
radnp
via
rout
also
experienc
sever
weight
loss
compar
sl
immun
group
protect
lethal
challeng
interestingli
howev
immun
pfu
radnp
provid
protect
challeng
dose
viru
figur
taken
togeth
data
demonstr
radnp
immun
via
rout
sl
rout
provid
complet
protect
heterolog
heterosubtyp
viru
challeng
suggest
high
dose
intranas
immun
may
requir
confer
protect
viru
challeng
complet
protect
offer
immun
radnp
heterolog
heterosubtyp
viru
challeng
render
us
investig
whether
observ
crossprotect
correl
magnitud
npspecif
tcell
respons
given
influenza
np
contain
conserv
immunodomin
tcell
epitop
indic
previous
order
determin
possibl
presenc
correl
blood
lymphocyt
mice
challeng
ld
dose
influenza
aphilippin
analyz
k
np
tetram
stain
day
day
postchalleng
expect
anim
receiv
control
radmock
immun
radnp
immun
via
sl
rout
succumb
death
day
postchalleng
figur
howev
immun
radnp
notwithstand
administ
dose
confer
complet
protect
figur
moreov
day
postchalleng
signific
increas
percentag
np
tetramerposit
blood
lymphocyt
observ
mice
immun
via
rout
greater
proport
npspecif
blood
lymphocyt
observ
mice
receiv
immun
pfu
dose
radnp
mice
receiv
pfu
dose
figur
taken
togeth
result
strongli
suggest
npspecif
cell
prime
radnp
immun
success
recal
subsequ
heterosubtyp
influenza
viru
infect
ascrib
crossprotect
observ
previou
figur
recent
abrupt
outbreak
influenza
pandem
caus
new
swinehumanavianorigin
influenza
viru
rais
signific
concern
global
public
health
awar
necess
better
prepared
potenti
recurr
influenza
pandem
current
inactiv
liveattenu
influenza
vaccin
wide
use
vaccin
human
howev
efficaci
vaccin
larg
depend
antigen
related
vaccin
viru
circul
influenza
viru
strain
given
influenza
viru
highli
dynam
viru
readili
undergo
genet
shift
drift
develop
vaccin
offer
previou
studi
identifi
influenza
viru
np
major
target
antigen
crossreact
influenza
virusspecif
cell
suggest
strategi
induc
npspecif
cell
consid
develop
broadli
protect
influenza
viru
vaccin
accordingli
engin
recombin
adenoviru
express
fulllength
np
deriv
influenza
viru
potenti
vaccin
candid
order
investig
whether
prime
npspecif
immun
respons
could
offer
crossprotect
differ
strain
subtyp
influenza
viru
howev
use
adenovirusbas
vaccin
rais
import
concern
regard
develop
vectorspecif
immun
vaccin
recipi
preexist
vector
immun
could
interfer
vaccin
efficaci
scenario
requir
multipl
booster
vaccin
address
challeng
chose
administ
recombin
adenoviru
vaccin
via
mucos
rout
previou
studi
shown
singl
immun
via
nasal
rout
bypass
develop
vectorspecif
immun
adenoviru
vector
human
elicit
potent
immun
respons
specif
vaccin
antigen
moreov
airway
mucosa
main
entri
point
variou
invad
pathogen
function
first
line
defens
respiratori
infect
mucos
immun
system
distinct
system
immun
system
possess
distinctli
organ
immunolog
tissu
function
maintain
homeostasi
within
mucosa
current
method
deliv
influenza
vaccin
via
parenter
rout
reli
system
induct
virusspecif
igg
protect
howev
previou
studi
report
influenza
vaccin
efficaci
also
close
associ
immun
respons
induc
within
respiratori
mucosa
given
parenter
influenza
vaccin
present
use
ineffici
stimul
immun
respons
mucos
tissu
studi
examin
potenti
applic
mucos
immun
strategi
shown
effect
target
system
mucos
immun
howev
safeti
issu
concern
redirect
antigen
central
nervou
system
immun
sl
rout
thought
rel
safe
therefor
present
studi
assess
sl
immun
approach
evalu
protect
efficaci
gener
mucos
vaccin
radbas
influenza
vaccin
two
rout
immun
shown
promot
induct
protect
immun
respons
character
local
respons
respiratori
mucosa
well
system
induct
vaccin
antigenspecif
respons
addit
aspect
studi
focus
comparison
humor
cellmedi
immun
respons
gener
follow
administr
vaccin
viru
via
two
differ
mucos
rout
want
determin
specif
branch
immun
prime
mucos
radnp
immun
correl
establish
crossprotect
differ
influenza
viru
strain
present
studi
demonstr
radnp
immun
increas
frequenc
npspecif
cell
recruit
lung
immun
mice
follow
homolog
challeng
viru
accordingli
complet
protect
challeng
observ
group
receiv
vaccin
viru
via
rout
indic
npspecif
ctl
respons
may
directli
correl
protect
homolog
influenza
viru
infect
moreov
protect
heterosubtyp
influenza
viru
infect
may
also
correl
npspecif
ctl
respons
npspecif
blood
lymphocyt
level
consider
increas
start
day
postchalleng
mice
surviv
lethal
challeng
heterosubtyp
viru
howev
immun
fail
confer
complet
protect
infect
mice
group
given
pfu
dose
radnp
surviv
lethal
challeng
explan
lack
protect
viru
although
immunodomin
tcell
epitop
within
np
np
fulli
conserv
among
influenza
subtyp
magnitud
characterist
ctl
respons
elicit
differenti
influenza
viru
infect
may
distinct
influenza
viru
strain
caus
concurr
infect
henc
even
subtl
differ
ctl
respons
may
affect
degre
protect
offer
influenza
infect
caus
differ
influenza
viru
strain
mucos
immun
mice
radnp
also
dramat
increas
npspecif
igg
level
serum
independ
immun
rout
howev
observ
subsequ
challeng
homolog
influenza
viru
addit
increas
npspecif
serum
igg
level
immun
mice
sl
immun
mice
substanti
level
npspecif
respiratori
mucos
iga
detect
immun
mice
wherea
iga
detect
sl
immun
mice
thu
possibl
presenc
influenza
npspecif
igg
iga
respiratori
mucosa
may
also
involv
protect
lethal
influenza
challeng
even
though
exact
mechan
remain
determin
immun
adenoviru
vector
encod
np
induc
cellular
antibodi
respons
shown
recent
influenza
virusinfect
cell
elimin
iggmedi
cellular
cytotox
phagocytosi
sinc
cell
express
surfac
infect
similarli
npspecif
antibodi
may
interact
viral
np
express
cell
surfac
infect
cell
mediat
cell
lysi
antibodydepend
cellular
cytotox
overal
studi
demonstr
singl
administr
radnp
confer
crossprotect
lethal
challeng
differ
influenza
viru
strain
sl
administr
vaccin
fail
confer
protect
ascrib
high
level
npspecif
ctl
antibodi
found
intranas
immun
mice
observ
crossprotect
given
influenza
np
contain
conserv
immunodomin
tcell
epitop
share
among
influenza
viru
mucos
immun
stimul
mucos
system
immun
respons
believ
immun
radnp
induc
protect
immun
differ
strain
influenza
viru
prime
crossreact
npspecif
ctl
respons
possibl
local
system
induct
npspecif
antibodi
vaccin
approach
examin
present
studi
could
explor
nextgener
influenza
vaccin
strategi
could
gener
broadli
protect
immun
multipl
influenza
viru
strain
thu
greatli
reduc
influenza
virusrel
public
health
burden
